Today Valeant Pharmaceuticals Intl Inc Stock Crashes

 Today Valeant Pharmaceuticals Intl Inc Stock Crashes

The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) is a huge mover today! About 365,592 shares traded hands. Valeant Pharmaceuticals Intl Inc (TSE:VRX) has declined 43.43% since April 19, 2016 and is downtrending. It has underperformed by 48.76% the S&P500.
The move comes after 8 months negative chart setup for the $7.66B company. It was reported on Nov, 23 by Barchart.com. We have $21.93 PT which if reached, will make TSE:VRX worth $383.00 million less.

Valeant Pharmaceuticals Intl Inc (TSE:VRX) Ratings Coverage

Out of 3 analysts covering Valeant Pharmaceuticals International (TSE:VRX), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. $74 is the highest target while $17 is the lowest. The $31.33 average target is 35.75% above today’s ($23.08) stock price. Valeant Pharmaceuticals International has been the topic of 17 analyst reports since October 20, 2015 according to StockzIntelligence Inc. The company was maintained on Monday, June 27 by RBC Capital Markets. The firm earned “Sector Perform” rating on Tuesday, May 24 by RBC Capital Markets. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) has “Sector Perform” rating given on Tuesday, September 20 by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Sector Perform” on Wednesday, September 7. The rating was maintained by TD Securities with “Hold” on Wednesday, July 20. The company was maintained on Monday, October 31 by RBC Capital Markets. The company was maintained on Tuesday, January 26 by RBC Capital Markets. The stock has “Sector Perform” rating given by RBC Capital Markets on Friday, June 3. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned “Sector Perform” rating by RBC Capital Markets on Monday, June 20. The firm has “Buy” rating by TD Securities given on Thursday, August 11.

More notable recent Valeant Pharmaceuticals Intl Inc (TSE:VRX) news were published by: Fool.ca which released: “Will Canopy Growth Corp. Crash as Hard as Valeant Pharmaceuticals Intl Inc.?” on November 23, 2016, also Business.Financialpost.com with their article: “Valeant Pharmaceuticals International needs to do a lot more than just cry …” published on November 21, 2016, Fool.com published: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” on November 08, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (TSE:VRX) were released by: Profitconfidential.com and their article: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” published on November 10, 2016 as well as Investorplace.com‘s news article titled: “Valeant Pharmaceuticals Intl Inc (VRX) Stock Owners Should Ask Tougher Questions” with publication date: November 15, 2016.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $7.66 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

VRX.TO Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment